- Home
- EGY vs RIGL Comparison
EGY vs RIGL Comparison
Compare EGY & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGY
- RIGL
- Stock Information
- Founded
- EGY 1985
- RIGL 1996
- Country
- EGY United States
- RIGL United States
- Employees
- EGY N/A
- RIGL N/A
- Industry
- EGY Oil & Gas Production
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- EGY Energy
- RIGL Health Care
- Exchange
- EGY Nasdaq
- RIGL Nasdaq
- Market Cap
- EGY 340.3M
- RIGL 335.5M
- IPO Year
- EGY N/A
- RIGL 2000
- Fundamental
- Price
- EGY $3.84
- RIGL $18.93
- Analyst Decision
- EGY
- RIGL Buy
- Analyst Count
- EGY 0
- RIGL 5
- Target Price
- EGY N/A
- RIGL $36.40
- AVG Volume (30 Days)
- EGY 1.1M
- RIGL 186.9K
- Earning Date
- EGY 08-05-2025
- RIGL 08-05-2025
- Dividend Yield
- EGY 6.53%
- RIGL N/A
- EPS Growth
- EGY N/A
- RIGL N/A
- EPS
- EGY 0.56
- RIGL 2.08
- Revenue
- EGY $489,162,000.00
- RIGL $203,077,000.00
- Revenue This Year
- EGY N/A
- RIGL $14.41
- Revenue Next Year
- EGY $24.62
- RIGL $15.97
- P/E Ratio
- EGY $6.89
- RIGL $9.09
- Revenue Growth
- EGY 3.02
- RIGL 70.16
- 52 Week Low
- EGY $3.00
- RIGL $7.48
- 52 Week High
- EGY $7.43
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- EGY 64.80
- RIGL 41.53
- Support Level
- EGY $3.30
- RIGL $21.04
- Resistance Level
- EGY $4.04
- RIGL $21.51
- Average True Range (ATR)
- EGY 0.15
- RIGL 0.99
- MACD
- EGY 0.05
- RIGL -0.27
- Stochastic Oscillator
- EGY 81.66
- RIGL 2.19
About EGY VAALCO Energy Inc.
VAALCO Energy Inc is an independent energy company operating in the United States. It is principally engaged in the acquisition, exploration, development, and production of crude oil and natural gas. The company operates through geographical segments namely Gabon, Egypt, Canada, Equatorial Guinea, and Cote d'Ivoire. The company generates maximum revenue from the Gabon segment.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.